Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug

Inclusion Criteria: * Participant must be ≥18 years of age inclusive, at the time of signing the informed consent. * Presence of the putative biomarkers of DDR deficiency in tumor and/or other tissues (dose escalation only). * Participants must have histologically confirmed solid tumors . * Eastern Cooperative Oncology Group performance status (ECOG-PS) of 0 to 1. * Adequate bone marrow function as assessed by laboratory tests to be conducted within 7 days before the first dose of study intervention. * Participants must have adequate kidney function, as assessed by the estimated glomerular filtration rate (eGFR) \> 40 mL/min per 1.73 m\*2 within 7 days before the first dose of study intervention. * Participants must have adequate liver function as assessed by laboratory tests to be conducted within 7 days before the first dose of study intervention. * Participants must have adequate coagulation, as assessed by laboratory tests as applicable, (to be conducted within 7 days before the first dose of study intervention) or be on stable anti-coagulation treatment. * Adequate cardiac function per institutional normal measured by echocardiography (recommended) or multigated acquisition (MUGA) scan/cardiac MRI per institutional guidelines. * Participants must have measurable disease (at least one measurable lesion) as per RECIST 1.1, or evaluable disease according to the Prostate Cancer Clinical Trials Working Group 3 (PCWG3) classification as applicable. Lesions situated in a previ…